An analysis of real-world data showed that Tepezza helped improve visual acuity in patients with dysthyroid optic neuropathy, according to a press release.
Data presented at the North American Neuro-Ophthalmology Society (NANOS) Annual Meeting on March 11-16 in Orlando Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.